Sucampo Appoints Dipak Panigrahi, MS, MD, as Vice President, Medical Affairs
Published on Wednesday, 20 June 2012 07:07 Written by TradersHuddle StaffBETHESDA, Md.-( Business Wire )-
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that Dipak Panigrahi, MS, MD, has joined the company as Vice President, Medical Affairs, a newly created position to expand our activity in this area. He will report to Thomas J. Knapp, Executive Vice President, Chief Legal Officer & Corporate Secretary. Dr. Panigrahi now leads Sucampo’s global Medical Affairs efforts, including establishing and leading our Medical Science Liaison (MSL) department and has assumed responsibility for medical message development, publications planning, key opinion leader development and providing advice on clinical trial design and development.
Ryuji Ueno, MD, PhD, PhD, Chair, CEO and CSO, said, “We welcome Dr. Panigrahi to Sucampo and look forward to his fulfilling a primary role in our communications with key physicians and scientific leaders across all our therapeutic areas. The broad range of his experiences, both as a physician in the clinic and in the pharmaceutical industry, will add great value to the AMITIZA® and RESCULA® brands. As a company that remains particularly focused on scientific advancements and research, our MSL team will be a key value driver in communicating those messages to the medical community. Our planned launch of RESCULA®, later this year in the US, will be one of our major events for Sucampo and will move us closer to becoming a fully integrated pharmaceutical company that discovers, develops, manufactures and commercializes its own products.”
Dr. Panigrahi joins Sucampo from Provision Pharmaceutical Consulting, a boutique contract pharmaceutical support firm, which he joined in March 2011. Prior to Provision, Dr. Panigrahi was Senior Vice President, R&D and Chief Medical Officer of QLT Inc. with overall responsibility for the planning, development, implementation and supervision of all phases of that company’s global research and development. Prior to joining QLT, Dr. Penigrahi was Vice President, Glaucoma Development at Alcon Laboratories, Inc. from July 2009 to March 2010. At Alcon, he was responsible for planning, developing and supervising all phases of global glaucoma pharmaceutical development. Previously, Dr. Penigrahi had been Associate Director at Merck & Co. Dr. Panigrahi earned a BA from John Hopkins University, an MD and MS, in Medical Sciences, from Hahnemann School of Medicine, interned in Internal Medicine at Mercy Medical Center/University of Maryland and completed his training with a residency in Ophthalmology at Georgetown-Washington Hospital Center.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a global pharmaceutical company is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.
RESCULA is a registered trademark of R-Tech Ueno, Ltd., and has been licensed to Sucampo.
Sucampo Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo’s ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo’s business, particularly those mentioned in the risk factors and cautionary statements in Sucampo’s Form 10-K for the year ended Dec. 31, 2011, which the Company incorporates by reference.
Related Partner Headlines
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) - TheStreet.com
- Sucampo Pharma Says FDA Has Granted Priority Review Status to Amitiza - Benzinga
- Sucampo Pharma Gets UK Approval for Amitiza - Benzinga
- Sucampo Pharmaceuticals Announces One-to-One Conversion of Class B Common Stock into Class A Common Stock - Benzinga
- Sucampo Pharmaceuticals Down 25% on Arbitration Decision - Benzinga
- Sucampo and Abbott Announce Approval for AMITIZA in Japan - Benzinga
- Sucampo Pharmaceuticals Provides Update on Anticipated Arbitration Decision; The ICC Extends Date to July 31 - Benzinga
- Sucampo Pharmaceuticals Inc. A Stock Downgraded (SCMP) - TheStreet.com
- Change in Date of Anticipated Arbitration Decision in Sucampo Pharmaceuticals Dispute - Benzinga
- Sucampo Presents Data for AMITIZA in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation - Benzinga
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,294.50 Trade time:4:53PM EDT Value change:▼12.67 (-0.08%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,650.51 Trade time:4:52PM EDT Value change:▼4.84 (-0.29%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,459.42 Trade time:5:15PM EDT Value change:▼3.88 (-0.11%)
In The Wires
Gold Fields Limited: Talas Copper Gold Project
InterOil And Pacific LNG Group Enter Into Exclusive Negotiations With ExxonMobil On Development Of The Elk And Antelope Resource
Gold Fields Limited: Talas Copper Gold Project
Hemp, Inc. Inks Investment Deal with 'Hemp America the Revolution' & 'Hemp Canada Seeds of Growth' Doc/Films
Novelis Expands Production Capacity in Europe for Automotive Sheet
Aegon Appoints Global Chief Technology Officer
3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement
China Zenix Auto International Announces Financial Results for the First Quarter of 2013